GenomOncology To Enable CompanionDx™ Clinical Cancer Panels

Westlake, OH. February 6, 2014 - GenomOncology announced today that CompanionDx™ has selected the company's GO Clinical Workbench™ to launch a series of next generation sequencing (NGS)-based assays related to cancer. CompanionDx™ will leverage GenomOncology's GO Clinical Workbench to manage the entire workflow: from raw sequencing data through delivery of an actionable clinical report to the client.

CompanionDx™ is a provider of both personalized pharmacogenomics evaluations and cancer companion diagnostic testing. When used separately or in conjunction, these two types of tests give physicians the resources necessary to develop comprehensive patient treatment profiles, thereby creating more certainty in therapeutic decisions. 

David Lasecki, President of CompanionDx™, commented "As we develop new tests that leverage next generation sequencing, we require a solution that meets our current needs but is scalable over time. GenomOncology's platform and services will allow us to efficiently add new cancer panels and expand our testing options to best serve our clients." 

The GO Clinical Workbench provides the laboratory with a fully traceable analysis workflow and rules-based decision support tool for the clinical interpretation of somatic mutations.  

"Providing the oncologist with actionable data that is specific to a patient's tumor in days instead of weeks adds to the medical utility of next generation sequencing," added Manuel Glynias, President and CEO of GenomOncology. "The convergence of discovery, technology, and therapeutic development has created an unparalleled opportunity to improve clinical outcomes for many patients with cancer." 

About CompanionDx™

With locations in the world-renowned Texas Medical Center in Houston and in Honolulu, Hawaii, CompanionDx™ Reference Lab is a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing. CompanionDx™ is committed to the next evolution in cancer care where comprehensive genetic data is delivered in an actionable format, thereby enabling the physician to make treatment decisions and choose healthcare strategies based on unique cancer type and the genetic makeup of each patient. CompanionDx™'s comprehensive and tumor-specific panels, coupled with personalized pharmacogenomic analysis, provide a unique offering that allows physicians to choose relevant and targeted therapies. For more information call David Lasecki at (330) 687-0807 or visit the company's website atwww.companiondxlab.com.  

About GenomOncology 

GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient's tumor genome into an actionable clinical report.  GenomOncology's research platform, GenomAnalytics™, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company's website atwww.genomoncology.com. 

For more information regarding this announcement, please contact: 

Jane Krug, PR Contact 

Phone: 504-390-5935

Email:  jane@genomoncology.com